The Largest & Original (Est. 2009) Forum for Precision Medicine
The Largest & Original (Est. 2009) Forum for Precision Medicine
Facilitating Collaboration in the Field of Personalized Patient Care
The Largest & Original (Est. 2009) Forum for Precision Medicine
Facilitating Collaboration in the Field of Personalized Patient Care
See the 7-Track, 3-Day, 400-Speaker Precision Medicine Agenda
See the 7-Track, 3-Day, 400-Speaker Precision Medicine Agenda
















Apply by SEP. 28 !

The Foremost Precision Medicine Conference

• Gathering recognized leaders, top global researchers and medical professionals, plus innovators across healthcare and biotechnology sectors

• Showcasing latest practical content that helps close the knowledge gap among different sectors

• Promoting cross-functional fertilization & collaboration to accelerate Precision Medicine

• Main Tracks and Showcases (6 Total) that provide a mix of established and upcoming perspectives

• Luminary and Pioneer Award Ceremony honoring those who transform healthcare by advancing precision medicine in the clinic

PMWC provides a valuable insight for physicians and others who may be wondering how close we are getting to realizing the arrival of personalized medicine. The conferences are helpful in understanding where and how the envelope is being pushed.

Peter Paul Yu, MD, FACP, FASCO, Immediate Past President, ASCO

See Testimonials video >

PMWC has proven, time and time again, that it attracts thought-leaders from all the relevant fields and catalyzes crucial collaboration through inspiring and practical program content. This is the Conference for entrepreneurs to meet payors, and for researchers to connect with service providers and for clinicians to hear from leading providers.

Lee Hood, PhD, MD, President, Institute for Systems Biology

See Testimonials video >

Bringing Together






Tickets to PMWC - Est. 2009

Sale ends
Loading Waiver
Loading Waiver
Addon Price:
+1 Extra Ticket:

Ticket Rate $0.00 $0.00 $0.00 $0.00

Credit card entry
Place Order & Next Step
This is an error.

Receive the latest news about the field of precision medicine and the conference from Tal Behar, PMWC’s President:

Hi Healthcare Professional,

We recently engaged in a discussion with Daphne Koller, CEO and founder of insitro and keynote speaker for the AI & Data Science Track at the PMWC 2024. The event is being held January 24-26, 2024 in Silicon Valley (FULL 6-TRACK PROGRAM SCHEDULE), and will explore opportunities and advancements that are emerging through the intersection of AI and data science.

As Koller shared in our conversation, we are currently witnessing an exponential trajectory in how data science and AI/ML can be applied to accelerate development cycle timelines across industries and the broad impact it is making on society. A notable instance is the recent launch of ChatGPT, which occurred only 10 months ago but is already evolving and influencing operations across various disciplines and professional domains. In alignment with this trend, AI and data science are projected to revolutionize every facet of drug discovery, clinical care and basic research.

“We find ourselves in a world where AI/ML can accomplish even more – advancing at such an accelerated pace and surpassing what would not have been achievable merely a month ago.”

Within healthcare, precision oncology stands out as one area with the swiftest advancement and subsequent deployment of AI/ML applications, Koller explained. Consider the case of breast cancer diagnosis – while early stages of AI/ML integration allowed for the identification of breast lumps, defining distinct cancer subtypes and understanding how to uniquely address them demanded the utilization of advanced data tools. As AI/ML has been further integrated into drug development and cancer diagnosis, we’ve come to understand the importance of treating certain cancers based on unique features. For example, we now know that HER-2 positive breast cancer patients should be treated differently than patients with BRCA1-based breast cancer. The data feeding into these decisions are already more intricate than what visual inspection by a human can encompass – an algorithm effectively handles this task by analyzing genetic data and translating it into recommended treatment choices.

Moving ahead, Koller believes the next generation of cancer treatments will involve subtle patterns in circulating DNA and methylation patterns, as well as integrating ML-enabled insights from histopathology, both requiring analysis beyond what a clinician can readily execute. Instead, a trained algorithm will be responsible for conducting the analysis. This shift will lead AI to play a more central role in making cancer predictions (e.g., cancer origin, driver mutations) and subsequent treatment determinations. Looking beyond cancer, other therapeutic areas will also reap benefits from advances in AI and data science.

“One imperative to drive field progress involves the collection of abundant high-content patient data, secure placement within anonymized research environments, and controlled researcher access within an appropriate data security framework. This will enable the unraveling of human disease heterogeneity and identification of treatable patient groups. This is increasingly pivotal, given that many conditions currently classified as diseases are highly likely not singular entities. Alzheimer’s, for example, isn’t a single disease, neither is autism or any condition in the mental health spectrum.”

“While we have seen these tremendous advances, our healthcare system is not fully armed with the tools necessary to deliver on the promise of what this technology can do. There continues to be inadequate system-wide patient data collection, and when sufficient data is able to be amassed, it often remains locked in data silos accessible to a handful of principal investigators involved in research.”

Koller emphasized that this approach doesn’t offer a winning strategy for our industry as a whole – or, more importantly, for patients. “Initiatives that have transcended these barriers, like the UK Biobank or The Cancer Genome Atlas, have profoundly reshaped the medical discipline. We should strive for more initiatives of this kind in order to truly unlock the potential of AI/ML for the benefit of patients – an effort so many of us in this industry have committed our lives and careers to.”

We are thrilled to present an outstanding data science track for PMWC 2024 Silicon Valley, scheduled for January 24-26, see the agenda for where Daphne is giving a keynote (Track 2 – January 26th):

Track Chair: Gad Getz, Broad Institute

• PMWC 2024 Luminary Award
Luminary Honoree: Heidi Rehm, MGH and Broad Institute
• Opening Talk: The Power of Data by Track Chair Gaddy Getz, Broad Institute
• Global Data Sharing Collaboration: Overcoming Organizational and Sectoral Barriers (PANEL)
Chair: Gad Getz, Broad Institute
– Peter Goodhand, GA4GH
– Valentina Di Francesco, NHGRI
• Challenges of Remote Data Harmonization and Querying
Chair: Heidi Rhem, MGH and Broad Institute
– Andrea Ramirez, All of Us
– Ida Sim, UCSF
– Josh Peterson, Emerge/Vanderbilt University Medical Center
– Nara Sobreira, Johns Hopkins/GeneMatcher
• Keynote: Machine Learning for Therapeutic Discovery
– Daphne Koller, insitro
• Exploring the Power of AI and Data Sciences in Drug Discovery
Chair: Russ Altman, Stanford University
– Kim Branson, GSK
– Sun-Gou Ji, BridgeBio
– Angela Oliveira Pisco, Insitro
• Foundation Models to Advance Precision Medicine (PANEL)
Chair: Nigam Shah, Stanford
– Aashima Gupta, Google
– Matthew Lungren, Microsoft
– Rod Tarrago, AWS

We invite you to join key opinion leaders in the field, ensuring you don’t miss out on these crucial discussions that are poised to shape decision-making across all healthcare and medical facets. Precision medicine, with its focus on granular comprehension and targeted treatment at both the patient population and individual patient levels, stands on the brink of significant advances facilitated by these emerging, increasingly potent AI systems and capabilities.

Join us January 24-26 (Link by Thursday) to participate in this critical discourse and witness the profound transformation in progress.


Tal Behar

President & Co-founder, PMWC
PMWC 2024 Silicon Valley – January 24-26, 2024

The Precision Medicine World Conference (PMWC)

Sent to [email protected] –

Stop receiving these emails

Although the health of women has generally seen some improvements over the years, it is still insufficiently supported when it comes to clinical study representation in funding research and in drug development. Women’s health as a medical specialty should include a comprehensive slate of physical, mental, and social well-being and not just focus narrowly on the absence of disease. To achieve this, sex differences should be considered. Sex differences contribute to health conditions such as polycystic ovary syndrome (PCOS), endometriosis, menopause (with all its side-effects), as well as higher prevalence of certain diseases (e.g., autoimmune diseases, long Covid-19, heart disease, and mental illnesses), all of which affect prevention, diagnosis, treatment, and overall health outcomes.

Women are underrepresented in clinical trials, even though it is well-known that drugs are metabolized differently in women and men. It is encouraging to see that the NIH has now an office fully dedicated to research women’s health trying to ensure that roughly half of all participants in NIH-funded trials are women.
Funding of research for women is not aligned with burdens of disease – in fact funding for women’s health research is undervalued and understudied.

Janine Austin Clayton, NIH and PMWC January 24-26, 2024 Luminary Awardee: “Sex is an important biological variable that needs to be rigorously accounted for in the biomedical continuum from the laboratory to the clinic. … We can do an even better job of addressing complex public health problems by looking at male and female differences and by studying both sexes in the lab, the clinic, and when delivering care.”

We are at an incredibly exciting time with the intersection of data, technology, and healthcare which should allow us to focus on the health of women more intensely from an interdisciplinary angle to make true advances. Researching women’s health as a distinct discipline allows for a deeper understanding of unique aspects of women’s experiences and physiology. For this exact reason, PMWC 2024 Silicon Valley will have a track fully dedicated to women’s health.

See the Just-Released Full PMWC January 24-26, 2024 Silicon Valley PROGRAM here.

We’re proud to present the lineup of key leaders contributing to the Women’s Health Track (Track 3), which is co-chaired by Yoel Sadovsky (Magee Women’s Research Institute) and Noel Bairey Merz (Barbara Streisand Women’s Heart Center, Cedars Sinai Medical Center):

Pioneer Award HonoreeDavid Page (MIT) will be honored for his groundbreaking discoveries in sex chromosome biology, including the unique properties of the Y chromosome and the genetic basis of sex differences in health and reproductive traits.
Luminary Award HonoreeJanine Austin Clayton (NIH) will be honored for her influential work to advance women’s health through the promotion of research inclusion and the study of sex differences.
Keynote: David Page (MIT) keynote: The Chromosomal Basis of Sex Differences in Health and Disease
Keynote: Janine Austin Clayton (NIH): Enhancing Women’s Health Research
General Sex Differences in Large Studies
Karen Reue (UCLA) will focus on Sex Differences in Metabolic Disease and how the prevalence and presentation of cardiometabolic diseases is sex-biased
Franck Mauvis-Jarvis (Tulane University) will discuss Sex Differences in Insulin Resistance
Feto-placental Sex Differences – chaired by Yoel Sadovsky (University of Pittsburgh)
Nima Aghaeepour (Stanford University) will dive into AI Taxonomy for Reproductive Health
Leslie Myatt (OHSU Oregon) will discuss Fetal Sex and Pregnancy Outcomes
Systems and Sex Differences
Marcia Stefanick (Stanford University) will talk about Sex differences in Cancer
Sabra Klein (JHU) will present on Sex Differences in Immunity to Viruses
Judy Regensteiner (University of Colorado) will discuss Sex and Gender with a Focus on Diabetes
Cardiovascular Sex Differences – chaired by Noel Bairey Merz (Cedars Sinai Medical Center)
Sex Differences in Alzheimer’s Disease (AD)
Marina Sirota (UCSF) will dive into Sex Differences in Alzheimer’s Disease (AD) Using Clinical, Molecular, and Computational Approaches
Sarah Banks (UCSD) will discuss Sex Differences in Tau Pathology and AD Risk
Roberta Brinton (University of Arizona) will present Hormone Therapy and Implications for Alzheimer’s Disease
Sex Differences and Cognitive-behavioral Function
Debra Kaysen (Stanford University) will focus on Gender Effects on Trauma Exposure, PTSD, and Treatment
Larry Cahill (UCI) will discuss Sex Influences on the Brain

Please join us and participate in this truly important matter at PMWC Silicon Valley, January 24-26, 2024. Register today to secure your spot.

I hope to see you join this important discussion and help drive positive change in this critical area of human health.


Tal Behar

President & Co-founder, PMWC
PMWC 2024 Silicon Valley – January 24-26, 2024

The Precision Medicine World Conference (PMWC)

The lack of specific guidelines on how to adjust medications based on genetic test results, and the difficulty in translating genetic test results into actionable prescribing decisions for affected drugs are the main reasons for the slow adoption of pharmacogenomic testing in the clinical setting.

The Clinical Pharmacogenetics Implementation Consortium (CPIC), an international consortium dedicated to facilitating the use of pharmacogenomic testing in patient care, has as a goal to address these clinical implementation barriers by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines. CPIC guidelines are designed to provide all information needed to interpret a pharmacogenomic test result, from defining haplotypes/alleles (e.g., CYP2D6*1/*5) to translating to a clinical phenotype (e.g., CYP2D6 intermediate metabolizer) and determining how to alter drug prescribing based on the phenotype assignment.

Kelly Caudle, St. Jude Children’s Research Hospital, Co-PI/Director CPIC, and Pharmacogenomics (PGx) Track Chair at PMWC January 24-26, 2024 Silicon ValleyThe lack of standardization in pharmacogenomic testing and reporting leads to issues with interoperability and portability of results, resulting in increased workload and cost for implementation and need for extensive training of clinicians. Furthermore, the lack of standardization can be misleading and confusing to many clinicians, resulting in distrust and misinterpretation of results.

Even though, the CPIC guidelines and projects have been endorsed by several professional societies, including the Association for Molecular Pathology (AMP), many testing laboratories are not aware of those guidelines. In fact, many different labs are using different reporting guidelines, disconnected from CPIC guidelines which results in discordance. To change this path, work is underway to create Standard Operating Procedures (SOPs) that will help the use of standardized genotype-phenotype relationships in order to create clear recommendations for clinical decision making by healthcare professionals, patients, and other stakeholders.

Kelly CaudleUltimately, clinical practice and patient care would be improved if more efficient exchange of information between laboratories and EHR systems would be allowed. Consistent interpretation of genetic information, efficient clinical training and competencies and consistent reimbursement policies are also needed.

We urge you to forward this email to any individuals or organizations involved in PGx testing who would benefit from standardizing their genotype-phenotype relationships and implementing the CPIC guidelines for improved patient care.

This important and pertinent precision medicine topic includes the following talks in PMWC 2024 PGx track chaired by Kelly Caudle, St. Jude Children’s Research Hospital (See Developing Program), and with thought leaders in the field:

• PMWC 2024 PGx Award Ceremony:
Pioneer Honoree: Russ Altman, Stanford
Pioneer Honoree: Andrea Gaedigk, University of Kansas
Luminary Honoree: Teri E. Klein, Stanford
• Standardization: Key to Advancing Precision Medicine
Opening Talk: Kelly E. Caudle, St. Jude
• Current and Desired States of Standardization of Clinical Laboratory Processes
Chair: Andrea Gaedigk, University of Kansas
– Vicky Pratt, Agena Bioscience
Chair: Damon Hostin, Illumina
– Howard McLeod, Intermountain Health
• Current and Desired States of Standardization of Reporting
Chair: Chad Bousman, University of Calgary
– Vicky Pratt, Agena Bioscience
– Lisa Brown
– Susanne Haga, Duke
• Current and Desired States of Standardization of Pharmacogenomic Test Ordering and Reimbursement (PANEL)
Chair: Sara Rogers, American Society of Pharmacovigilance
– Jai Patel, Atrium Health
– Greg Warren, Axene Health Partners
• Current and Desired State of PGx Education
Chair: Phil Empey, University of Pittsburgh
– Teri E. Klein, Stanford
• Current and Desired State of the Patient Experience in Precision Medicine
Chair: Avni Santani, LetsGetChecked
• Clinical Pearls and Outcome Data: Advancing the Adoption of Pharmacogenomics in Clinical Practice
Chair: Kelly E. Caudle, St. Jude
– Larisa H Cavallari, University of Florida
– Jeff Bishop, University of Minnesota

Secure your spot and participate in the discussion about the future of PGx and beyond by registering now for PMWC Silicon Valley, January 24-26, 2024.
Note there are various ticket types available and group discounts.


Tal Behar


Follow PMWC on these social networks

#PMWC24 Follow PMWC on these social networks

PMWC Overview


PMWC, the “Precision Medicine World Conference” is the largest & original annual conference dedicated to precision medicine. PMWC’s mission is to bring together recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization & collaboration in an effort to accelerate the development and spread of precision medicine.

Since 2009, recognized as a vital cornerstone for all constituents of the health care and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology (e.g. DNA sequencing technology), in clinical implementation (e.g. cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors.



The conference format consists of five parallel talks spanning 3 full days. Main Tracks 1-4 include sessions by leaders in the commercial, pharmaceutical, academic, government, regulatory, venture capital, and non-profit arenas that deliver a broad and up-to-date array of content across the various facets of precision medicine. Session discussions focus on time-relevant aspects with a selected set of key stakeholders, while commercial sessions cover the latest developments in technologies that are instrumental for the success of further adoption of precision medicine.

Additional 2 Tracks, feature Showcases: companies and research institutions can promote their platforms, launch products, and share research developments to a targeted audience(Apply) & the Most Promising Company Competition: identifies “rising stars” startup companies in the area of diagnostics, therapeutics, and health tech via a platform that includes leading investors.

For over a decade, PMWC has recognized individuals who have played a significant role in transforming health care by advancing precision medicine in the clinic with the Luminary and Pioneer Awards. The honorees’ numerous technological and scientific contributions have expedited this transformation as demonstrated by the clinical adoption of precision medicine, and the ongoing introductions of novel clinical applications. For a deeper look into the fascinating achievements of our past awardees see the awards page.


Add Names/PO on Receipt

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts

Apply to Speak at PMWC Silicon Valley by SEP. 28TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required